Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Rhea-AI Summary
Verve Therapeutics, a clinical-stage biotechnology company focused on developing genetic medicines for cardiovascular disease, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's co-founder and CEO, Sekar Kathiresan, M.D., will engage in a fireside chat on Wednesday, February 5, 2025 at 9 a.m. ET in New York.
The event will be accessible via a live webcast through the investor section of Verve's website at www.vervetx.com. For those unable to attend live, the presentation will remain archived on the website for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – VERV
In the trading session that priced this news, VERV gained 6.21%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York.
A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 90 days following the presentation.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company’s lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
